No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.
about
Fingolimod for relapsing-remitting multiple sclerosisFingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidenceAlemtuzumab in Multiple Sclerosis: Mechanism of Action and BeyondA practical review of the neuropathology and neuroimaging of multiple sclerosis.A scoping review of indirect comparison methods and applications using individual patient dataEffect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema.Review and comparison of methodologies for indirect comparison of clinical trial results: an illustration with ranibizumab and aflibercept.Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple SclerosisHow to run a multiple sclerosis relapse clinic.Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice.Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage ("Neuroprotection").Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal.Therapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future Directions.Dimethyl Fumarate: A Review in Relapsing-Remitting MS.Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis.Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up.Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.Trajectory of MS disease course for men and women over three eras.Pharmacodynamic effects of daclizumab in the intrathecal compartment."No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA.Bringing the HEET: The Argument for High-Efficacy Early Treatment for Pediatric-Onset Multiple Sclerosis.Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis.No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers
P2860
Q24185882-7163FA5B-9B2C-4399-BD50-E90B69D4052CQ26752466-C0E0CEC0-E618-4833-98D7-4633DC143A90Q26800128-BCF6F32A-F1AA-4419-83E9-464987E19A16Q31062386-31FCADDF-3E1A-47BA-A6E7-DE354ED51256Q31085484-0A41FF00-1B9B-4A64-8E09-B443D0B108E9Q33628626-3DFB98B4-BEEB-47B0-BB01-245A631E1C2FQ35846504-031D2D95-A119-48AE-BBB1-0ACD69D020DEQ35948351-A4B4EC42-362B-4D44-BC42-8F1B1F943038Q35954145-3A03D294-70DD-4F51-BF48-9A82DCF70EF9Q36275984-E9420845-496A-4293-B168-67F3D2DC0EBCQ36484448-CAC23ECD-12F0-483A-8BAF-5097299BC1B1Q36577187-A4AE94A6-754F-4EF3-84EC-385AC036B62CQ37684523-E18A2D0E-7970-4448-9217-DBCBD6A86CBDQ38379260-7D7A75FC-C485-4B38-B5DB-36BFAAF8A6F4Q38534132-3B5C938D-A98D-4139-B0CA-90C0BC4DA6EFQ38666303-485A2ADB-C4F1-450C-94EE-E2DA77667E9EQ38675014-D8FC9F98-9528-4B34-AFA4-75392670B7ACQ39234479-EA222E54-590D-4B2C-8654-FBDF3A0E9178Q39298719-C0E98957-E142-435B-9082-9396AD4D1819Q40048497-61BFE432-73D8-41F5-A575-04A478103662Q40090879-20D0F84E-5639-4169-8234-C4BE5F53F808Q40672999-20E69B89-904E-4CB5-91AA-69DCF9D4188FQ40962441-DF120C0F-5E16-4755-A6C9-8ECE4581AA6DQ41185260-1C0A79F7-1D6E-48D7-A6FA-2A23B144159BQ47255582-19C490BE-81E9-4FFE-A84E-CF679C35192FQ48664001-F60B76AA-85C9-4D81-B0FC-AB868DDBECA3Q48711608-48CA315E-AAAB-4307-BF10-7CBBF2456D04Q50111623-B66787E7-21F3-4241-AECE-A315F967DC4AQ52641471-FE91A126-4FE7-4C52-956D-4FAAC9BD3C05Q58805531-9FDF49AC-33A0-4120-9CD8-BC2BACF37152
P2860
No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
No evidence of disease activit ...... -remitting multiple sclerosis.
@ast
No evidence of disease activit ...... -remitting multiple sclerosis.
@en
No evidence of disease activit ...... -remitting multiple sclerosis.
@nl
type
label
No evidence of disease activit ...... -remitting multiple sclerosis.
@ast
No evidence of disease activit ...... -remitting multiple sclerosis.
@en
No evidence of disease activit ...... -remitting multiple sclerosis.
@nl
prefLabel
No evidence of disease activit ...... -remitting multiple sclerosis.
@ast
No evidence of disease activit ...... -remitting multiple sclerosis.
@en
No evidence of disease activit ...... -remitting multiple sclerosis.
@nl
P2093
P2860
P1433
P1476
No evidence of disease activit ...... -remitting multiple sclerosis.
@en
P2093
Davorka Tomic
Gary Cutter
Niklas Bergvall
Nikolaos Sfikas
Richard Nixon
P2860
P2888
P304
P356
10.1007/S12325-014-0167-Z
P407
P577
2014-11-21T00:00:00Z
P5875
P6179
1012807175